Searched for
CANCER DRUGMAKER
Defence startups raid auto and fracking sectors for parts to speed weapons outputSoaring demand for rocket motors used to power missiles and other weapons has spurred new thinking about supply chains. Seeking big returns...- Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Global Markets: European shares edge higher with banks in the lead; the Middle East in focusEuropean markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after ...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
- Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
- Novartis sharpening India strategy as a pure-play innovatorNovartis India country president and managing director Amitabh Dube said India is gradually moving beyond its traditional role as a clinica...
- US stocks today: Nasdaq falls as technology stocks slide, Treasury yields climbUS stocks closed mixed as Nasdaq slipped due to profit booking and rising Treasury yields, while Dow edged higher. Oil prices surged on sup...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
- Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata MotorsIndian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL,...
- Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: SourcesIndian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acqu...
- Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatmentA major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement c...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weighLondon’s FTSE 100 edged lower as losses in energy majors and AstraZeneca weighed on the index amid thin holiday trading. Weak crude prices ...
Load More
